INTRODUCTION

Psoriasis is a chronic, immune-mediated polygenic skin disorder characterized by epidermal hyperplasia. Cardinal histopathological features are as follows: hyperkeratosis, parakeratosis, neutrophils in the stratum corneum and spinous layer, hypogranulosis with suprapapillary thinning, acanthosis, clubbed rete ridges, dilated capillaries, and perivascular lymphocytes. As histopathology may be more definitive compared to clinical manifestations, being able to diagnose psoriasis accurately through histopathology may enable early diagnosis and treatment. This could ideally mean a decrease in its progression, prevention of complications, and improvement of quality of life for psoriatic persons.

To examine, grade, and compare histopathologic f indings of psoriatic lesions with established parameters from previous literature.

This is a retrospective descriptive study that will examine, grade, and compare all histopathologic findings of psoriatic lesions of patients who have accessed care at Ospital ng Manila Medical Center from 2010-2015 with established parameters from previous literature.

All 41 cases (100%) showed parakeratosis, followed in decreasing order by 19 cases (46.34%) with Munro's microabscesses, 15 cases (36.59%) with pustules of Koga, 15 cases (36.59%) with hypogranulosis, and 11 cases (26.83%) with spongiosis. Using the visual analogue scale of Moorchung Net al (2013), 28 cases (68.29%) showed mild inflammatory infiltrates, followed in decreasing order by 19 cases (46.34%) with mild epidermal hyperplasia, 12 cases (29.27%) with mild capillary proliferation, and 4 cases (9.77%) with mild suprapapillary thinning.

Findings of the current study showed histopathologic features of both early and fully developed lesions based on established psoriasis histopathological parameters. Recognized histopathological features were not consistently found in well-developed lesions.

BACKGROUND

Psoriasis is an increasingly prevalent chronic disease commonly treated with topical corticosteroids (TCS), although these agents are often misused. There is a need to explore the factors influencing nonadherence to TCS among patients with psoriasis in the Philippines. This study aimed to determine the knowledge, attitude, and practice (KAP) regarding TCS among Filipino patients with psoriasis.

A cross-sectional survey was conducted on 76 Filipino patients with psoriasis at a tertiary hospital using a constructed validated questionnaire.

Patient scores clustered at the upper end of the distribution, indicating a generally good level of KAP regarding TCS. Increasing age was associated with a lower level of knowledge, while female respondents had a higher level of knowledge. Higher knowledge levels were associated with better patient attitude, and better patient attitude was associated with better practice.

Predictors of correct KAP regarding TCS are less likely influenced by sociodemographic and clinical factors; rather, these three domains significantly correlate with each other. Physicians can utilize these interrelationships by educating patients regarding their topical treatment to yield more positive attitudes regarding its efficacy and minimize their fear of side effects, which can motivate them to adhere to prescribed therapy.

OBJECTIVE: To determine the role of Tripterygium wilfordii multiglycoside (TGW) in the treatment of psoriatic dermatitis from a cellular immunological perspective. METHODS: Mouse models of psoriatic dermatitis were established by imiquimod (IMQ). Twelve male BALB/c mice were assigned to IMQ or IMQ₊TGW groups according to a random number table. Histopathological changes in vivo were assessed by hematoxylin and eosin staining. Ratios of immune cells and cytokines in mice, as well as PAM212 cell proliferation in vitro were assessed by flow cytometry. Pro-inflammatory cytokine expression was determined using reverse transcription quantitative polymerase chain reaction. RESULTS: TGW significantly ameliorated the severity of IMQ-induced psoriasis-like mouse skin lesions and restrained the activation of CD45⁺ cells, neutrophils and T lymphocytes (all P<0.01). Moreover, TGW significantly attenuated keratinocytes (KCs) proliferation and downregulated the mRNA levels of inflammatory cytokines including interleukin (IL)-17A, IL-23, tumor necrosis factor α, and chemokine (C-X-C motif) ligand 1 (P<0.01 or P<0.05). Furthermore, it reduced the number of γ δ T17 cells in skin lesion of mice and draining lymph nodes (P<0.01). CONCLUSIONS TGW improved psoriasis-like inflammation by inhibiting KCs proliferation, as well as the associated immune cells and cytokine expression. It inhibited IL-17 secretion from γ δ T cells, which improved the immune-inflammatory microenvironment of psoriasis.
Male ; Animals ; Mice ; Tripterygium ; Psoriasis/drug therapy* ; Keratinocytes ; Skin Diseases/metabolism* ; Cytokines/metabolism* ; Imiquimod/metabolism* ; Dermatitis/pathology* ; Disease Models, Animal ; Mice, Inbred BALB C ; Skin/metabolism*

Humans ; Arthritis, Psoriatic/drug therapy* ; Interleukin-17 ; Interleukin Inhibitors ; Antirheumatic Agents/therapeutic use* ; Tumor Necrosis Factor-alpha/therapeutic use* ; Interleukin-23/therapeutic use*

Pemphigus foliaceous is a rare autoimmune blistering disease, while psoriasis is a common immune‑mediated inflammatory skin disease. The coexistence of psoriasis and pemphigus foliaceous has rarely been reported. We report a case of a 55‑year‑old Filipino female with an 8‑year history of chronic plaque‑type psoriasis biopsy‑proven. After 5 years, she developed generalized flaccid bullae and crusted erosions over the face, trunk, and extremities, with no mucous membrane involvement. Skin punch biopsy, direct immunofluorescence, and enzyme‑linked immunosorbent assay were consistent with pemphigus foliaceous. The combination of topical corticosteroids and oral methotrexate was selected as the therapeutic approach, leading to a notable improvement in the patient’s condition. This case report underscores the significance of identifying the simultaneous presence of psoriasis alongside autoimmune blistering diseases like pemphigus foliaceous. Examining predisposing and triggering factors, performing re‑biopsy, and further work‑up as the disease evolves may yield more profound insights. Nonetheless, effectively managing this condition poses a significant challenge.
Fluorescent Antibody Technique, Direct ; Methotrexate ; Psoriasis

Pityriasis rubra pilaris (PRP) is a rare and challenging dermatological condition that often mimics other skin disorders, complicating diagnosis and management. This case is unique due to the patient’s comorbidities, which restricted treatment options and required a shift from conventional therapy to biologic treatment.

A 57-year-old male presented with a three-week history of an itchy rash on the face, neck, and upper extremities after sun exposure. Initial treatment with topical corticosteroids was ineffective, and the condition progressed to involve the trunk and lower extremities with erythroderma. Additional findings included hyperkeratosis of the palms and soles, psoriatic plaques on the elbows, and thickened toenails with onychomycosis. Histopathology revealed superficial psoriasiform dermatitis, consistent with PRP. Methotrexate (12.5 mg/week) was initiated, leading to initial improvement. However, a relapse occurred after five months, and due to elevated liver enzymes, a dose increase was not feasible. Secukinumab, an IL-17A inhibitor, was subsequently recommended by the clinic consilium. Already after one month, significant improvement was observed, and near-complete remission was achieved by four months. The patient continues treatment with secukinumab with a satisfactory clinical response and minimal residual symptoms.

This case underscores the complexities of diagnosing and managing PRP, particularly when comorbidities limit standard treatment options. The successful use of secukinumab, despite the failure of conventional therapy, demonstrates the potential of biologics in managing PRP, especially in refractory cases. It highlights the importance of personalized treatment strategies in optimizing outcomes for patients with complex dermatological conditions.

Erythrodermic psoriasis is the least common and most severe variant of psoriasis manifesting as erythema and scaling affecting more than 75% body surface area. Infections, such as COVID-19, are proposed triggers due to provoking immune responses that can progress into a hyperinflammatory state. We present a case of a patient with a history of psoriasis evolving into an erythrodermic form after infection with COVID-19 virus.

A 50-year-old female, clinically diagnosed with plaque type psoriasis for 12 years, sought emergency consult then was admitted due to persistence of generalized erythematous scaly plaques, with accompanying skin and joint pains as well as high grade fever. Definitive diagnosis was done with clinicopathologic correlation including dermoscopy and skin punch biopsy. The patient’s Psoriasis Area and Severity Index (PASI) was 70.2, indicating severe score. SARS-COV-2 RT-PCR was done, revealing a positive result for the causative agent of COVID-19. A multidisciplinary approach to treatment was done with dermatology, rheumatology, and infectious disease services. Medications include antibiotics, antimetabolites, pain medications, and topical steroids. The patient was discharged then would follow-up with the dermatologist with phototherapy and with the rheumatologist. After completing treatment, most lesions have recovered.

Erythrodermic psoriasis is a severe and uncommon form of psoriasis that may be exacerbated by various infections such as COVID-19. Proper history, physical examination, and use of diagnostic procedures can aid in pinpointing the cause of the disease which will be indispensable in managing such patients.

Acrodermatitis continua of Hallopeau (ACH) is a chronic, rare pustular form of psoriasis that affects the distal extremities, particularly the fingers and toes. Although pustules are characteristic, they may not always be clinically apparent, especially in the earlier stages. This condition is often resistant to treatment; therefore, early and accurate diagnosis is essential for proper management and preventing complications.

A 34-year-old male farmer presented with a one-year history of pruritic erythematous scaly plaques involving both palms, thumbs and thumbnails. Pertinent history showed that the lesions appeared after contact with rubber gloves and fertilizers. Irritant versus allergic contact dermatitis were considered, but a negative patch test result ruled out the allergic component. He was treated with topical corticosteroids and was advised to wear cotton gloves under rubber gloves while working which provided relief. However, the plaques recurred now with appearance of pustules on both hands. A skin punch biopsy was done revealing psoriasiform dermatitis with subcorneal pustules, consistent with ACH. The patient was started on methotrexate 7.5 mg/week and topical clobetasol, alternating with calcipotriol with improvement of the palmar plaques and pustules.

ACH is often misdiagnosed due to its pus-filled lesions which may mimic infection or secondarily infected contact dermatitis or dyshidrotic eczema. In this case, the initial presentation mimicked a contact dermatitis, and it was only after patch testing and skin biopsy, that a definitive diagnosis was made.

Human immunodeficiency virus (HIV) leads to immunosuppression by depleting CD4+ T-cells. Psoriasis, a common immune-mediated inflammatory dermatosis, can paradoxically worsen or emerge as an initial presentation of HIV. The introduction of highly active antiretroviral therapy (HAART) in psoriatic patients with HIV may trigger severe psoriasis flare-ups, often linked to immune reconstitution inflammatory syndrome (IRIS).

This case involves a 31-year-old Filipino male with recurrent, resistant psoriatic plaques. Further testing revealed latent syphilis and HIV infection. The patient completed treatment for syphilis and began HAART, but developed erythrodermic psoriasis, likely due to IRIS. After an inadequate response to acitretin, guselkumab, an IL-23 inhibitor, was administered. The patient responded well, showing significant improvement after four months of treatment without adverse effects.

This case suggests that in severely immunocompromised patients with newly diagnosed HIV, adding guselkumab to conventional HAART may be a safe and effective option for controlling erythrodermic psoriasis flares triggered by immune reconstitution. However, further research is needed to assess the long-term safety and efficacy of guselkumab in HIV-associated psoriasis.

Psoriasis may manifest as severe hyperkeratotic lesions resembling an oyster shell called ostraceous psoriasis. This type of psoriasis is extremely rare and is often associated with psoriatic arthritis. Psoriatic arthritis is a chronic inflammatory disease of the joints presenting with pain, stiffness, swelling, tenderness, and limited movements. This is a case of a 16-year-old Filipino female presenting with pruritic erythematous plaques topped with thick adherent ostraceous scales associated with bilateral knee and elbow pains. Laboratory tests and biopsy were done. Histopathology is consistent with psoriasiform dermatitis and psoriatic arthritis is established through Early Psoriatic Arthritis (EARP) Screening Questionnaire and Classification Criteria for Psoriatic Arthritis (CASPAR). Patient was started on potent topical corticosteroids and Narrow-band Ultraviolet B (NB-UVB) phototherapy with minimal improvement. Hence, Secukinumab was initiated which showed significant improvement on the skin lesions and joint pains 7 days after the first dose of Secukinumab. Ostraceous psoriasis is rarely found in pediatric population. It is commonly associated with psoriatic arthritis that should be screened during routine consult. Its characteristic firmly adherent thick scales are resistant to topical treatments. One of the therapeutic options is Secukinumab, an IL-17A selective inhibitor targeting the release of proinflammatory cytokines, chemokines and mediators of tissue damage. It demonstrates immediate effect, significant and sustained improvement in the skin lesions, minimal adverse reactions, as well as improved quality of life and physical function. It is therefore a preferred treatment for patients with moderate to severe psoriasis and psoriatic arthritis requiring rapid clearance.